[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1245146A1 - 尿酸性或痛風性疾病的預防或治療 - Google Patents

尿酸性或痛風性疾病的預防或治療

Info

Publication number
HK1245146A1
HK1245146A1 HK18104884.1A HK18104884A HK1245146A1 HK 1245146 A1 HK1245146 A1 HK 1245146A1 HK 18104884 A HK18104884 A HK 18104884A HK 1245146 A1 HK1245146 A1 HK 1245146A1
Authority
HK
Hong Kong
Prior art keywords
prevention
treatment
uric acid
gout disease
gout
Prior art date
Application number
HK18104884.1A
Other languages
English (en)
Inventor
張倩
黃振華
劉金榮
遲雙雙
Original Assignee
上海珊頓醫藥科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海珊頓醫藥科技有限公司 filed Critical 上海珊頓醫藥科技有限公司
Publication of HK1245146A1 publication Critical patent/HK1245146A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18104884.1A 2015-01-30 2018-04-16 尿酸性或痛風性疾病的預防或治療 HK1245146A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201510048096 2015-01-30
CN201510080714 2015-02-13
CN201510079809 2015-02-13
CN201510216089 2015-04-30
PCT/CN2016/000061 WO2016119570A1 (zh) 2015-01-30 2016-01-28 尿酸性或痛风性疾病的预防或治疗

Publications (1)

Publication Number Publication Date
HK1245146A1 true HK1245146A1 (zh) 2018-08-24

Family

ID=56542370

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18103914.7A HK1244434A1 (zh) 2015-01-30 2018-03-21 尿酸性或痛風性疾病的預防或治療
HK18104884.1A HK1245146A1 (zh) 2015-01-30 2018-04-16 尿酸性或痛風性疾病的預防或治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK18103914.7A HK1244434A1 (zh) 2015-01-30 2018-03-21 尿酸性或痛風性疾病的預防或治療

Country Status (26)

Country Link
US (1) US10322132B2 (zh)
EP (1) EP3251675B1 (zh)
JP (1) JP6678685B2 (zh)
KR (1) KR102128810B1 (zh)
CN (1) CN107206002B (zh)
AU (1) AU2016212625B2 (zh)
BR (1) BR112017016065A2 (zh)
CA (1) CA2973746C (zh)
CY (1) CY1124383T1 (zh)
DK (1) DK3251675T3 (zh)
EA (1) EA034139B1 (zh)
ES (1) ES2881872T3 (zh)
HK (2) HK1244434A1 (zh)
HR (1) HRP20211007T1 (zh)
HU (1) HUE054741T2 (zh)
IL (1) IL253726B2 (zh)
LT (1) LT3251675T (zh)
MA (1) MA41431B1 (zh)
MX (1) MX2017009853A (zh)
PL (1) PL3251675T3 (zh)
PT (1) PT3251675T (zh)
SG (2) SG11201705889VA (zh)
SI (1) SI3251675T1 (zh)
TW (1) TWI680761B (zh)
WO (1) WO2016119570A1 (zh)
ZA (1) ZA201704600B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024179463A1 (zh) * 2023-02-27 2024-09-06 珊顿医药科技新加坡公司 化合物8-氯-3-戊基-3,7-二氢-1h-嘌呤-2,6-二酮的晶型及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
AU3725893A (en) * 1992-02-21 1993-09-13 Smithkline Beecham Corporation TNF inhibitors
AR015966A1 (es) 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
WO2005077950A2 (en) * 2004-02-14 2005-08-25 Smithkline Beecham Corporation Medicaments with hm74a receptor activity
CN101479273B (zh) * 2006-06-23 2011-11-30 英赛特股份有限公司 作为hm74a激动剂的嘌呤酮衍生物
AU2007260852B2 (en) * 2006-06-23 2013-01-10 Incyte Corporation Purinone derivatives as HM74a agonists
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
US20110136835A1 (en) * 2009-09-14 2011-06-09 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
WO2011057110A1 (en) 2009-11-06 2011-05-12 Ruprecht-Karls-Universitat-Heidelberg Gpr109a agonists for the treatment of cerebral ischemia

Also Published As

Publication number Publication date
SI3251675T1 (sl) 2021-08-31
HUE054741T2 (hu) 2021-09-28
DK3251675T3 (da) 2021-06-28
EP3251675B1 (en) 2021-04-21
LT3251675T (lt) 2021-07-12
IL253726B2 (en) 2023-07-01
CA2973746C (en) 2020-03-24
JP2018503691A (ja) 2018-02-08
ZA201704600B (en) 2020-07-29
CN107206002B (zh) 2019-07-16
PL3251675T3 (pl) 2021-11-02
MA41431A (fr) 2017-12-06
MA41431B1 (fr) 2021-05-31
AU2016212625B2 (en) 2020-03-26
JP6678685B2 (ja) 2020-04-08
TWI680761B (zh) 2020-01-01
EP3251675A1 (en) 2017-12-06
BR112017016065A2 (zh) 2018-04-03
IL253726B1 (en) 2023-03-01
MX2017009853A (es) 2017-11-01
SG10201907026RA (en) 2019-09-27
TW201628623A (zh) 2016-08-16
SG11201705889VA (en) 2017-08-30
EP3251675A4 (en) 2018-06-20
KR20170106485A (ko) 2017-09-20
WO2016119570A1 (zh) 2016-08-04
PT3251675T (pt) 2021-05-25
CA2973746A1 (en) 2016-08-04
CN107206002A (zh) 2017-09-26
AU2016212625A1 (en) 2017-07-27
US10322132B2 (en) 2019-06-18
EA201791714A1 (ru) 2017-11-30
HK1244434A1 (zh) 2018-08-10
US20170326148A1 (en) 2017-11-16
ES2881872T3 (es) 2021-11-30
EA034139B1 (ru) 2020-01-09
HRP20211007T1 (hr) 2021-09-17
KR102128810B1 (ko) 2020-07-02
IL253726A0 (en) 2017-09-28
CY1124383T1 (el) 2022-07-22

Similar Documents

Publication Publication Date Title
IL253945A0 (en) kdm1a inhibitors to treat the disease
RS60852B1 (sr) Upotreba kanabidiolne kiseline u lečenju epilepsije
IL283837A (en) Improved acid alpha-glucosidase for the treatment of Pompe disease
IL257960A (en) A group of substances used to treat or prevent hyperuricemia or gout
PT3481819T (pt) Compostos e a sua utilização para reduzir os níveis de ácido úrico
GB201515244D0 (en) Treatment of inflammatory disease or condition
GB201603546D0 (en) Treatment of urine
HK1246679A1 (zh) 絲蟲病的治療
HK1245146A1 (zh) 尿酸性或痛風性疾病的預防或治療
EP3377062C0 (en) AMINONAPHHOQUINONE COMPOUNDS FOR THE TREATMENT AND/OR PREVENTION OF FIBROSIS DISEASES
GB201514729D0 (en) Treatment of haemorrhoids
PL2975004T3 (pl) Obróbka kwasowych ścieków
HK1253014A1 (zh) 用於治療龐貝氏病的增强的酸性α-葡糖苷酶
GB201621398D0 (en) Treatment of emt-associated disease
GB201504413D0 (en) Treatment of disease
GB201501800D0 (en) Treatment of medical conditions
EP3854402C0 (en) TREATMENT OR PREVENTION OF GRAFT-VERSE-HOST DISEASE
GB201610906D0 (en) Treatment of cardiovascular disease
GB201517565D0 (en) Treatment of genetic diseases